CF
XBI icon

Concorde Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Concorde Financial’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-300
Closed -$33K – 142
2021
Q4 		$33K Buy
+300
New +$36.2K 0.02% 62

Other funds holding XBI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Concorde Financial's XBI Position: Q1 2022 in Review

Concorde Financial sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 300 shares — an estimated $33K sold.

Concorde Financial first reported a position in XBI in Q4 2021 and held it in 1 quarter. The position peaked at $33K in Q4 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.

  • Concorde Financial reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
  • Concorde Financial sold 300 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $33K.
  • Concorde Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2021 and held it in 1 quarter.
  • Concorde Financial's State Street SPDR S&P Biotech ETF position peaked at $33K in Q4 2021.
  • 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.

Based on Concorde Financial's 13F filing for Q1 2022, filed 16 May 2022.